Tackling the Opioid Epidemic

Laws and Regulations Applicable to APRN Prescribing of Controlled Substances

Activity Details
  • Credit Amounts:
    • CNE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Jan 24, 2017
  • Expires: Jan 23, 2020
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    (6 Ratings)


Pamela C.  Hagan Pamela C. Hagan, MSN, RN
APRN Education & Practice Consultant
Kentucky Board of Nursing
Louisville, Kentucky

Morgan C.  Ransdell Morgan C. Ransdell, JD
Prosecuting Attorney
Kentucky Board of Nursing
Frankfort, Kentucky

Needs Statement

Complaints received by the Kentucky Board of Nursing about current prescribing practices of controlled substances (Schedule II, III, IV, V) by APRNs indicate a lack of knowledge regarding current Kentucky laws and regulations governing prescriptive authority of controlled substances.

Target Audience

Health care providers needing to identify components of Kentucky laws and regulations that relate to standards and best practices for prescribing authority for controlled substances and care of patients


Upon completion of this educational activity, participants will be able to:

  • Review Kentucky laws affecting prescribers and nurses in general
  • Discuss the effects of HB1 on the prescribing practices of controlled substances by APRNs
  • Discuss the scope and standards of prescriptive authority as defined in KRS 314. 042, 201 KAR 20:057, 201 KAR 20:059, 201 KAR 20:063, and other relevant statutes and regulations
  • Describe the latest evidence related to the prescription of Naloxone
  • Apply KASPER requirements and Kentucky laws affecting prescribers


The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This educational activity is offered for a maximum of 1.00 ANCC contact hour.

The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. The University of Kentucky does not approve commercial products. This educational activity is offered for a maximum of 1.2 KBN contact hours.

Provider #: 3-0008-01-18- 882. In order to receive credit, participants complete this CNE activity and submit a credit application and evaluation form online. Certificates may be printed once the evaluation is completed.

UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

Michelle Lofwalll, MD (planner) has relevant financial relationships with commercial interests as follows:

  • Braeburn Pharmaceuticals - Consultant and Principal Investigator - Consulting Fees and Research Contract
  • PCM Scientific - Speaker - Honoraria

No speaker or other planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

CE Content Concerns


Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504


  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.